Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.47 |
| ▸ | BRAF | P15056 | 6/20 | 0.47 |
| ▸ | RAF1 | P04049 | 4/20 | 0.47 |
| ▸ | KRAS | P01116 | 3/20 | 0.47 |
| ▸ | RET | P07949 | 3/20 | 0.45 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.44 |
| ▸ | SIK1 | P57059 | 1/20 | 0.43 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.43 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.42 |
| ▸ | LCK | P06239 | 4/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.42 |
| ▸ | JAK3 | P52333 | 2/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.41 |
| ▸ | FLT3 | P36888 | 2/20 | 0.41 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.41 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.41 |
| ▸ | LTK | P29376 | 1/20 | 0.41 |
| ▸ | CDK8 | P49336 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5065340 | 0.92 | KDR (0.53) | KDRBRAFRAF1KRASRET | |
| SCHEMBL4274353 | 0.89 | BRAF (0.55) | KDRBRAFRAF1KRASRET | |
| SCHEMBL5067015 | 0.87 | BRAF (0.46) | KDRBRAFRAF1KRASMAP2K2 | |
| SCHEMBL4276391 | 0.87 | BRAF (0.46) | KDRBRAFRAF1KRASMAP2K2 | |
| SCHEMBL5062436 | 0.86 | KDR (0.48) | KDRBRAFRAF1KRASRET | |
| SCHEMBL4430448 | 0.86 | BRAF (0.44) | KDRBRAFRAF1KRASMAP2K2 | |
| SCHEMBL5057671 | 0.85 | SIK2 (0.53) | KDRBRAFRAF1KRASMAP2K2 | |
| SCHEMBL4425996 | 0.85 | KDR (0.57) | KDRBRAFRAF1KRASRET | |
| SCHEMBL4279385 | 0.85 | BRAF (0.43) | KDRBRAFRAF1KRASMAP2K2 | |
| SCHEMBL4429145 | 0.84 | KDR (0.45) | KDRBRAFRAF1KRASMAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080114006-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | claimed |
| US-20120289540-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-11-15 | — | — | US | disclosed |
| US-8188113-B2 | For example, 1-(5-(2-amino-8-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-yl)-2-fluorophenyl)-3-(3-tert-butyl-1-phenyl-1H-pyrazol-5-yl)urea; for treatment of mammalian cancers and inflammatory diseases including rheumatoid arthritis, retinopathies | DECIPHERA PHARMACEUTICALS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20080114006-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289540-A1 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | BRAF, PRKDC, RAF1 | KDR 500/4885BRAF 1/4885RAF1 3/4885 |
| US-20080114006-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | BRAF, PRKDC, RAF1 | KDR 500/4885BRAF 1/4885RAF1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.